OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
Rik J. Verheijden, Mick J M van Eijs, Anne M. May, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 52
Rik J. Verheijden, Mick J M van Eijs, Anne M. May, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 52
Showing 1-25 of 52 citing articles:
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 33
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 33
Severe cutaneous adverse reactions
Wen‐Hung Chung, Maja Mockenhaupt, Kimberly G. Blumenthal, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 18
Wen‐Hung Chung, Maja Mockenhaupt, Kimberly G. Blumenthal, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 18
Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges
Lily Dara, Eleonora De Martin
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 2
Lily Dara, Eleonora De Martin
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 2
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials
Rik J. Verheijden, Jolien S. de Groot, Babs O. Fabriek, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3713-3724
Closed Access | Times Cited: 13
Rik J. Verheijden, Jolien S. de Groot, Babs O. Fabriek, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3713-3724
Closed Access | Times Cited: 13
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
Rik J. Verheijden, F.H. Burgers, Josephine C Janssen, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114172-114172
Closed Access | Times Cited: 10
Rik J. Verheijden, F.H. Burgers, Josephine C Janssen, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114172-114172
Closed Access | Times Cited: 10
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
Theresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114028-114028
Open Access | Times Cited: 9
Theresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114028-114028
Open Access | Times Cited: 9
Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma
Jingwen Zhang, Anthony M. Joshua, Yue Li, et al.
Cancer Letters (2024) Vol. 586, pp. 216633-216633
Open Access | Times Cited: 8
Jingwen Zhang, Anthony M. Joshua, Yue Li, et al.
Cancer Letters (2024) Vol. 586, pp. 216633-216633
Open Access | Times Cited: 8
Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients
Tess Van Meerhaeghe, Naoka Murakami, Alaín Le Moine, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 7
Tess Van Meerhaeghe, Naoka Murakami, Alaín Le Moine, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 7
Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias
Ying Yu, Ning Chen, Sizhe Yu, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 3, pp. 751-764
Open Access | Times Cited: 5
Ying Yu, Ning Chen, Sizhe Yu, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 3, pp. 751-764
Open Access | Times Cited: 5
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Mario E. Lacouture, Elena Goleva, Neil J. Shah, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 13, pp. 2822-2834
Open Access | Times Cited: 5
Mario E. Lacouture, Elena Goleva, Neil J. Shah, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 13, pp. 2822-2834
Open Access | Times Cited: 5
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review
Thomas Ruli, Ethan D. Pollack, Atul Lodh, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2042-2042
Open Access | Times Cited: 5
Thomas Ruli, Ethan D. Pollack, Atul Lodh, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2042-2042
Open Access | Times Cited: 5
Acute respiratory distress syndrome (ARDS): from mechanistic insights to therapeutic strategies
Rongli Xie, Dan Tan, Boke Liu, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Rongli Xie, Dan Tan, Boke Liu, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
Xiuyue Man, Hong Wang, Chen Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Xiuyue Man, Hong Wang, Chen Chen, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Development of an intranodal drug delivery system using a mouse model with lymphadenopathy: novel discoveries and clinical application
Tetsuya Kodama, Ariunbuyan Sukhbaatar
Expert Opinion on Drug Delivery (2025)
Closed Access
Tetsuya Kodama, Ariunbuyan Sukhbaatar
Expert Opinion on Drug Delivery (2025)
Closed Access
Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy
Nežka Hribernik, Katja Strašek, Andrej Studen, et al.
Radiology and Oncology (2025) Vol. 59, Iss. 1, pp. 43-53
Open Access
Nežka Hribernik, Katja Strašek, Andrej Studen, et al.
Radiology and Oncology (2025) Vol. 59, Iss. 1, pp. 43-53
Open Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Steroid hormones as modulators of anti-tumoural immunity
Paul Schwarzlmüller, Alexandra Triebig, Guillaume Assié, et al.
Nature Reviews Endocrinology (2025)
Closed Access
Paul Schwarzlmüller, Alexandra Triebig, Guillaume Assié, et al.
Nature Reviews Endocrinology (2025)
Closed Access
Immunotherapy in gestational trophoblastic neoplasia: advances and future directions
Jing Zeng, Jing Zhang, Jianzhang Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Jing Zeng, Jing Zhang, Jianzhang Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immune checkpoint inhibitor-associated nephritis - treatment standard
Elena-Bianca Barbir, Abhijat Kitchlu, Sandra M. Herrmann
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 11, pp. 1785-1798
Closed Access | Times Cited: 4
Elena-Bianca Barbir, Abhijat Kitchlu, Sandra M. Herrmann
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 11, pp. 1785-1798
Closed Access | Times Cited: 4
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures
Chester Kao, Soren Charmsaz, Stephanie Alden, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 20
Open Access | Times Cited: 4
Chester Kao, Soren Charmsaz, Stephanie Alden, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 20
Open Access | Times Cited: 4
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature
Peng Ning, Shilan Liu, Hongyi Cao
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
Peng Ning, Shilan Liu, Hongyi Cao
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
Updates of the role of B-cells in ischemic stroke
Silin Wu, Sidra Tabassum, Cole T. Payne, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access | Times Cited: 3
Silin Wu, Sidra Tabassum, Cole T. Payne, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access | Times Cited: 3
Physical activity and checkpoint inhibition: association with toxicity and survival
Rik J. Verheijden, Anna Cabané Ballester, Karel C Smit, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 4, pp. 573-579
Open Access | Times Cited: 8
Rik J. Verheijden, Anna Cabané Ballester, Karel C Smit, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 4, pp. 573-579
Open Access | Times Cited: 8
The Current and Future of Biomarkers of Immune Related Adverse Events
William Bracamonte‐Baran, Sang T. Kim
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 201-227
Closed Access | Times Cited: 2
William Bracamonte‐Baran, Sang T. Kim
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 201-227
Closed Access | Times Cited: 2
